The Galapagos Decentralized Cell Therapy Manufacturing Platform

Galapagos is a biotech company with operations in EU and US, running clinical trials in phase 1 and 2 in Cell therapy (CAR-T) for Oncology. CAR-T is a personalized treatment methodology, where the immune cells from the patient are adapted and re-infused to the patient to attach the cancer cells. Galapagos is using a unique decentralized manufacturing approach compared to the other big players in the field like BMS, J&J, and Kite. This decentralized model has several advantages compared to the central manufacturing approach, such as the use of fresh material (over frozen), and a median vein-to-vein time of 7 days. Automation of our equipment and QC testing is a very important aspect of this to be able to meet this goal, and some examples will be shared in the presentation.

Speaker: Brigitta Witte, Galapagos